The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Fortress Biotech Subsidiary Closes $205 Million Priority Review Voucher Sale

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Cyprium Therapeutics, a subsidiary of Fortress Biotech, closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).

Cyprium Therapeutics, a subsidiary of Fortress Biotech (FBIO), has successfully finalized the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). The transaction generated gross proceeds of $205 million, marking a significant liquidity event for the company. Management characterized the deal as transformational for the corporate structures of both Cyprium and Fortress. This substantial cash infusion provides the biotechnology firm with non-dilutive capital to support its ongoing operations and strategic initiatives. The sale highlights the intrinsic value of regulatory assets in the biotech sector and strengthens the parent company's balance sheet. Investors view the move as a positive development that enhances financial flexibility without equity dilution.